Quick Answer
Cue Biopharma, Inc. reported Stockholders Equity of $26.43 million for the year ending 2025.
- Cue Biopharma, Inc. showed an increase of +51.0% in Stockholders Equity from 2024 to 2025.
- This data is from Cue Biopharma, Inc.'s annual report (Form 10-K), filed with the SEC on March 16, 2026.
- XBRL data for this metric is available from 2016 to 2025 (10 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2016: $15.18 million | Q1 2018: $55.26 million | Q2 2018: $49.23 million | Q3 2018: $39.40 million | Q1 2019: $24.74 million | Q2 2019: $20.28 million | Q3 2019: $27.02 million | Q1 2020: $45.24 million | Q2 2020: $80.15 million | Q3 2020: $87.55 million | Q1 2021: $69.67 million | Q2 2021: $72.91 million | Q3 2021: $63.52 million | Q1 2022: $64.67 million | Q2 2022: $59.76 million | Q3 2022: $50.76 million | Q1 2023: $55.02 million | Q2 2023: $46.00 million | Q3 2023: $42.67 million | Q1 2024: $30.04 million | Q2 2024: $21.62 million | Q3 2024: $25.37 million | Q1 2025: $6.58 million | Q2 2025: $18.16 million | Q3 2025: $13.25 million.
- Over the full 10 years of available data (2016 to 2025), Cue Biopharma, Inc.'s Stockholders Equity has grown by 74.2%.
- Historical annual values: Fiscal year 2025: $26.43 million | Fiscal year 2024: $17.50 million | Fiscal year 2023: $37.09 million | Fiscal year 2022: $65.68 million | Fiscal year 2021: $65.49 million | Fiscal year 2020: $78.91 million | Fiscal year 2019: $54.58 million | Fiscal year 2018: $33.97 million | Fiscal year 2017: $61.61 million | Fiscal year 2016: $15.17 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: